These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26568389)

  • 1. Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide.
    Igarashi T; Fujita M; Yamada Y; Kobayashi M; Fujimoto C; Takahashi H; Igarashi T; Nakano Y; Suzuki H; Takahashi H
    J Nippon Med Sch; 2015; 82(5):229-36. PubMed ID: 26568389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
    Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
    Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Rebamipide Instillation for Contact Lens Discomfort With Dry Eye.
    Igarashi T; Kobayashi M; Yaguchi C; Fujimoto C; Suzuki H; Takahashi H
    Eye Contact Lens; 2018 Nov; 44 Suppl 2(2):S137-S142. PubMed ID: 29135738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
    Ueda K; Matsumiya W; Otsuka K; Maeda Y; Nagai T; Nakamura M
    BMC Ophthalmol; 2015 Jun; 15():58. PubMed ID: 26048396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
    Kinoshita S; Awamura S; Nakamichi N; Suzuki H; Oshiden K; Yokoi N;
    Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.
    Koh S; Inoue Y; Sugmimoto T; Maeda N; Nishida K
    Cornea; 2013 Sep; 32(9):1219-23. PubMed ID: 23676786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
    Yamane M; Ogawa Y; Fukui M; Kamoi M; Saijo-Ban Y; Yaguchi S; Mukai S; Kawakita T; Simmura S; Tsubota K
    Optom Vis Sci; 2015 Apr; 92(4 Suppl 1):S25-32. PubMed ID: 25785527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery.
    Igarashi A; Kamiya K; Kobashi H; Shimizu K
    Cornea; 2015 Aug; 34(8):895-900. PubMed ID: 26020821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice.
    Ohguchi T; Kojima T; Ibrahim OM; Nagata T; Shimizu T; Shirasawa T; Kawakita T; Satake Y; Tsubota K; Shimazaki J; Ishida S
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7793-802. PubMed ID: 24168989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Comparison Between Rebamipide Ophthalmic Suspension and Diquafosol Ophthalmic Solution for Dry Eye After Penetrating Keratoplasty.
    Kobashi H; Kamiya K; Shimizu K
    J Ocul Pharmacol Ther; 2017; 33(1):13-18. PubMed ID: 27937084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of 2% Topical Rebamipide on Conjunctival Squamous Metaplasia and Goblet Cell Density in Dry Eye Disease.
    Simsek C; Dogru M; Shinzawa M; Den S; Kojima T; Iseda H; Suzuki M; Shibasaki Y; Yoshida N; Shimazaki J
    J Ocul Pharmacol Ther; 2019; 35(6):350-358. PubMed ID: 31259647
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions.
    Arimoto A; Kitagawa K; Mita N; Takahashi Y; Shibuya E; Sasaki H
    Cornea; 2014 Aug; 33(8):806-11. PubMed ID: 24977983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Tear Meniscus Dynamics Using Anterior Segment Swept-Source Optical Coherence Tomography After Topical Solution Instillation for Dry Eye.
    Akiyama-Fukuda R; Usui T; Yoshida T; Yamagami S
    Cornea; 2016 May; 35(5):654-8. PubMed ID: 26989953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
    Shamloo K; Barbarino A; Alfuraih S; Sharma A
    Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease.
    Takahashi Y; Ichinose A; Kakizaki H
    Am J Ophthalmol; 2014 Apr; 157(4):807-812.e2. PubMed ID: 24412123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effects of instillation of a rebamipide suspension on visual function.
    Kaido M; Ishida R; Dogru M; Tsubota K
    J Ocul Pharmacol Ther; 2014 May; 30(4):313-8. PubMed ID: 24506279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress.
    Simsek C; Kojima T; Nakamura S; Dogru M; Tsubota K
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Clinic-based Survey of Clinical Characteristics and Practice Pattern of Dry Eye in Japan.
    Kawashima M; Yamada M; Suwaki K; Shigeyasu C; Uchino M; Hiratsuka Y; Yokoi N; Tsubota K;
    Adv Ther; 2017 Mar; 34(3):732-743. PubMed ID: 28181147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.